STAR Ltd.

351.25.00INR -2.60 ( -0.73%) VOLUME : 911000
    Average Volume
  • 5-Day 1,435,000.00
  • 20-Day 1,727,500.00
  • 3-Months 1,551,650.00

MARKET CLOSED

Price Table

Date Open High GREEN: if High is higher than last 2 days high
RED: if high is lower than last 2 days high
Low GREEN:if Low is higher than last 2 days low
RED: if low is lower than last 2 days low
LTP Close GREEN:if Day's Closing is near the Day's High
RED: if low is lower than last 2 days low
Volume Delivery % 20 Day SMA GREEN: if Day's Closing is above 20-Day SMA
RED: if Day's Closing is below 20-Day SMA
50 Day SMA GREEN: if Day's Closing is above 50-Day SMA
RED: if Day's Closing is below 50-Day SMA
100 Day SMA GREEN: if Day's Closing is above 100-Day SMA
RED: if Day's Closing is below 100-Day SMA
200 Day SMA GREEN: if Day's Closing is above 200-Day SMA
RED: if Day's Closing is below 200-Day SMA
18-Oct-19 350.00 355.50 344.60 351.25 353.85 911,003 26% 332.22 368.39 382.34 421.05
17-Oct-19 348.15 355.25 344.15 353.00 353.85 882,963 17% 332.85 369.33 382.95 421.56
16-Oct-19 354.40 357.95 338.45 349.30 351.10 1,971,133 11% 333.47 369.96 383.52 422.10
15-Oct-19 333.00 358.80 333.00 355.00 355.60 1,984,603 11% 334.92 370.36 384.24 422.69
14-Oct-19 326.00 340.80 321.30 337.00 338.50 1,425,059 11% 336.75 370.31 384.82 423.26
11-Oct-19 314.00 327.05 309.40 326.00 324.40 1,491,641 8% 339.65 370.61 385.61 423.93
10-Oct-19 311.60 324.00 302.50 316.95 317.15 1,410,478 8% 343.35 371.00 386.55 424.65

Performance

Key Data

Day High Low Range

Time Lowest Highest
10 AM 347.70 353.95
11 AM 344.60 353.95
12 PM 344.60 353.95
1 PM 344.60 353.95
2 PM 344.60 353.95

Company Profile - STAR Ltd.

STAR In 2002, the Board approved for the allotment of about 210,955 shares of the company at INR 10 each to the shareholders of Bombay Drugs & Pharma Ltd. Also, Zenith Pharmaceuticals Ltd acquired about 71% shares via the preferential issue route. Also, the board approved for the proposal of restructuring its Cram division into the two separate companies under the provisions of the companies act. It incorporated the 'Strides Africa Ltd' at British Virgin Island with an authorized capital of US $ 200,000 as a 100% wholly-owned subsidiary. Also, the board decided to change the name of the company to 'Strides Arcolab (FA)' to reflect the change in the business focus and operations. In 2003, it nominated Mr. Francis Pinto as the Director on the Board of the company. It also forged an exclusive co-operation alliance with South Africa based drug manufacturer Aspen Pharmacare, mainly to share the product development expertise and quality systems. The Board ... approves for the reorganization of subsidiaries of the company and writes off of diminution in value of investments made in subsidiaries by the company. It signed an MoU with Ribbon SRL for Cephalosporin. In 2005, it also entered into an agreement with Mayne Pharma Business Unit of Australia based Mayne Group Ltd, to develop and manufacture a spectrum of six anti-infective products that Mayne will market and distribute in the US and European markets. It agreed on private placement issue and also signed a License Agreement with KV Pharma for exclusive marketing rights in the US and Canada for 10 new generic drugs. It acquired the sterile manufacturing facility in Poland. In 2007, it also received 2 more NDA approvals from US-FDA.

Some of the Milestones:

  • 2010:It informed that Mr. V. S. Iyer had been appointed as an Executive Director of the Company.
  • 2011: 
  • It received the US FDA NOD for commercializing the first Sterlite.
  • It declared the First European Approval for Oncology Product.
  • It updated regarding the acquisition of an outstanding minority shareholding in Ascent Pharmahealth Limited.
  • It joined the Malaysian Bio-xcell Ecosystem.
  • 2012:
  • It declared the US FDA approval for its 'Brazilian Sterile.'
  • It received the US FDA approval for Methotrexate Injection.
  • It declared Health Canada Approval For Tobramycin Injection.
  • It collaborated with Gilead Sciences.
  • 2013:
  • It received ANDA approval from USFDA for Tenofovir Disoproxil Fumarate and Emtricitabine Tablet.
  • It declared the US FDA approval for its Italian Semi-solids and Ointment facility.
  • It declared the WHO pre-qualification for Artemether + Lumifantrine.
  • Both StelisBiopharma and Pieris Forge Alliance for the Novel Anticalin.
  • Strides Arcolab - Both Pfenex Inc. and Agila Biotech Private Ltd declared Joint Venture for developing Biosimilar Products for the Global Market.
  • 2014:
  • It also made a strategic investment in Oncobiologics Inc., USA.
  • It partnered with Gilead Sciences Inc, to bring Hepatitis C cure to 91 developing countries.
  • It received the US FDA approval for Buspirone Tablets.
  • It received the US FDA approval for Calcitriol Softgel.
  • It acquired 'Raricap' and India Branded Generic Business of Bafna.
  • It acquired the Shasun Pharma in an all-stock deal.
  • 2015:
  • It also agreed with Fortuna Public Relations Pvt. Ltd., Delhi and also appointed them as the Company's Public Relations Agency.
  • It also entered into a licensing agreement with Gilead Sciences Inc.
  • It launched the generic drug Sofosbuvir in India.
  • It received the USFDA nod for Polyethylene Glycol 3350.
  • It received the USFDA nod for HIV treatment drug.
  • It accomplished the INR 1,910-crore acquisition of Aspen Pharmacare, Australia.
  • It also changed its name from its present name Strides Arcolab Limited to Strides Shasun Limited.
  • 2016:
  • It updated on the acquisition of seven brands from Johnson & Johnson.
  • It updated on the acquisition of CNS divisions of Ranbaxy.
  • It also acquired a strategic stake in Generic Partners Holdings, Australia.
  • It acquired the controlling stake in the universal Corporation, Kenya.
  • It received the USFDA Tentative Approval for Efavirenz Tablet.
  • The Strides Shasun declared the successful completion of the US FDA inspection at its Oral Dosage Facility in Bangalore.